ABVX
Abivax S.A.
NASDAQ · Healthcare · Biotechnology · FR
$114.71
+0.59%Next report
Analyst consensus
- Next report date
- Sep 21, 2026
- EPS estimate
- -$0.96
- Revenue estimate
- $778.5K
Latest reported
- Last report date
- May 22, 2026
- EPS actual
- -$0.71
- EPS estimate
- -$0.94
- Revenue actual
- $1.5M
- Revenue estimate
- $401.1K
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 4
- EPS misses (12Q)
- 2
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -22.1%
- Revenue beats (12Q)
- 5
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $158
- PT range
- $110 – $187
- Analysts
- 7
6 Buy1 Hold0 Sell
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Sep 21, 2026